

Bayer



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Patrick W. Thomas named new Management Board Chairman of Bayer MaterialScience AG

Current Chairman Dr. Hagen Noerenberg to retire

Leverkusen / August 10, 2006 – Patrick W. Thomas (48) has been named the new Chairman of the Board of Management of Bayer MaterialScience AG. British-born Thomas succeeds Dr. Hagen Noerenberg (59), who will retire from active service on December 31, 2006 after 30 years with the Bayer Group. Commented Bayer AG Management Board Chairman Werner Wenning: “Given his more than 25 years’ international experience in the chemical industry, we are convinced of Patrick Thomas’ ability to drive forward our business with high-tech polymer materials.”

Patrick W. Thomas was born on September 30, 1957 in Portsmouth, U.K. He left Oxford University with an engineering degree in 1979. The same year he began his career with British chemicals company Imperial Chemical Industries (ICI). Until 1989 he held a number of positions for ICI Pharmaceuticals and Agrochemicals (which became Zeneca in 1993) in the U.K. In 1989 Thomas transferred to Belgium to join ICI Polyurethanes, undertaking various management assignments until in 1993 he was named Regional Director for Europe, Africa & Middle East. Four years later he was appointed global CEO.

In 1999 Thomas joined U.S. chemicals company Huntsman as President of the Polyurethanes, Performance and Advanced Materials Divisions, also based in Belgium. In 2003 he was named Corporate Executive Vice President of Huntsman Matlin Patterson. Since 2005 he has been working as a management consultant for private-equity companies in the industry sector.

“I’m looking forward to working in a company with such a rich tradition as Bayer,” said Thomas, “and I’m very optimistic about the future of Bayer MaterialScience.” The

future CEO of Bayer MaterialScience, who will join the company on August 15, 2006, is married and has four children.

Dr. Hagen Noerenberg has been Chairman of the Board of Management of Bayer MaterialScience AG since January 1, 2004. Prior to that he headed up the Bayer Polymers business area. Hagen Noerenberg was born on January 31, 1947 in Holzminden. He studied chemistry at Göttingen and Braunschweig universities, obtaining his Ph.D. in 1975. The following year he began his career in the Research and Development Division of EC Erdölchemie GmbH, at that time a joint venture between Bayer and BP. He undertook various assignments for the company before being named Managing Director in 1998.

In 2000 Dr. Noerenberg became Head of the Plastics Business Group at Bayer and then, from November 2001, Head of the Polyurethanes Business Group. Said Wenning: "Hagen Noerenberg contributed very successfully to the reorganization of our polymers operations, the strategic realignment of Bayer MaterialScience and the considerable improvement in that company's performance."

Bayer MaterialScience AG is a global leader in high-tech materials and innovative system solutions. The company had sales of about EUR 10.7 billion in 2005 and employs some 18,800 people at more than 40 sites around the world.

Leverkusen, August 10, 2006

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)


Ilia Kürten (+49-214-30-35426)

Ute Menke (+49-214-30-33021)

Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.



Investor News

Innovative active ingredients to control fungal infections in cereals

Prothioconazole and fluoxastrobin receive marketing authorization in the important French market

Monheim / August 11, 2006 – Bayer CropScience has received marketing authorization for its active ingredients prothioconazole and fluoxastrobin in France, the biggest cereal fungicides market in the world. This means that both substances can be supplied to distributors this year and will be available in good time for the spring 2007 season.

Prothioconazole and fluoxastrobin are both products of Bayer CropScience's successful research and development pipeline and are some of the most promising active ingredients in the fungicides portfolio. Global sales of prothioconazole alone reached EUR 58 million in the first quarter of 2006, making it one of Bayer CropScience's fastest-growing substances. A broad application window, rapid uptake of the active substance by the plant, good rainfastness and long-lasting activity combine to create a new dimension in the control of plant diseases.

The company plans to market the two substances in France as a combination product for spray application to cereals under the tradename Fandango® S. It also intends to market prothioconazole in two combipacks: as an Input® pack (prothioconazole + spiroxamine) and as a Madison® pack (prothioconazole + trifloxystrobin). The spectrum of activity primarily encompasses leaf diseases, particularly leaf spot caused by *Septoria tritici*. The current development of resistance by this major cereal disease to strobilurins leaves users with few alternative modes of action. Products based on prothioconazole can be used as part of an effective resistance management program to control *Septoria tritici* and all diseases that affect the leaves, stem base and ear of cereals.

Prothioconazole, a member of the new class of triazolinethiones, was first approved in Germany in 2004 under the trademark Proline[®] and rapidly secured a large market share. Since then, users in a further 16 countries have been persuaded by the product's outstanding protective and curative action, and sales have grown well in the financially important fungicides market. The strobilurin fungicide fluoxastrobin was launched in 2005 in combination with prothioconazole as Fandango[®] in Germany, the UK and Ireland and is already well-established, particularly in barley.

Prothioconazole and fluoxastrobin are the result of intensive research and development work. Between 2000 and 2005, Bayer CropScience brought as many as 16 new active substances to market. A further 10 are expected to follow between 2006 and 2011. In total, the company believes that potential sales for its 26 new active substances could amount to approximately EUR 2 billion.

Bayer CropScience, a subsidiary of Bayer AG with annual sales of about EUR 6 billion, is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of about 19,000 and is represented in more than 120 countries. This and further news is available at: www.newsroom.bayercropscience.com

Monheim, August 11, 2006

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ilia Kürten (+49-214-30-35426)

Ute Menke (+49-214-30-33021)

Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.